Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis associated with external wind-heat syndrome [1] Group 1 - The clinical trial was organized by the company's subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. [1] - The trial is a significant step in the development of the company's product portfolio in the pharmaceutical sector [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its proprietary product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguanli Yan Oral Liquid received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for cold symptoms associated with wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially launched by Wanglaoji Pharmaceutical [1]

关于子公司药物进入 III 期临床试验的公告 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 王老吉药业2024年克感利咽口服液的销售额为人民币1,828.52万元，除王老吉药 业生产的克感利咽口服液外，中国境内上市的克感利咽颗粒的生产厂家有葵花药业集 1 团（襄阳）隆中有限公司、临江市宏大药业有限公司等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"公司"）子公司广州王老吉药业股份有限 公司（"王老吉药业"）于近日召开克感利咽口服液治疗急性咽炎（外感风热证）的 III期临床试验启动会，该III期临床试验项目正式启动。现将相关情况公告如下： 一、克感利咽口服液的基本情况 药物名称：克感利咽口服液 剂型：合剂 规格：10 mL/支 注册分类：2.3类新药 二、克感利咽口服液的其他情况 克感利咽口服液于1997年获得新药证书和生产批件，是王老吉药业独家品种，收 载于《中华人民共和国药典》2025年版一部，具有疏风清热，解毒利咽作用，主要用 ...

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥物進入III期臨床試驗的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年10月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 剂型：合剂 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 关于子公司药物进入 III 期临床试验的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白 ...

Core Viewpoint - Guangzhou Pharmaceutical Holdings Limited's subsidiary, Wanglaoji Pharmaceutical, has officially launched a Phase III clinical trial for its product, Keguanli Throat Oral Solution, aimed at treating acute pharyngitis [1] Group 1: Clinical Trial Details - The Phase III clinical trial for Keguanli Throat Oral Solution was initiated recently [1] - The product received its new drug certificate and production approval in 1997 and is listed in the 2025 edition of the Pharmacopoeia of the People's Republic of China [1] - The solution is indicated for symptoms related to wind-heat invasion and internal heat disturbance, primarily used for colds [1] Group 2: Regulatory Approvals - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024 [1] - The approval allows the company to conduct confirmatory clinical trials for acute pharyngitis [1]

Core Viewpoint - The announcement indicates that Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has officially launched the Phase III clinical trial for the drug Kegang Liyan Oral Liquid, aimed at treating acute pharyngitis [1] Group 1: Product Details - Kegang Liyan Oral Liquid is classified as a Class 2.3 new drug, with a specification of 10 mL per bottle, designed to dispel wind, clear heat, and detoxify [1] - The projected sales revenue for Kegang Liyan Oral Liquid in 2024 is estimated at RMB 18.2852 million [1] Group 2: Financial Investment - As of September 2025, the project has incurred research and development expenses of approximately RMB 18.1542 million (unaudited) [1]

Core Insights - Guangdong Pharmaceutical Yunshan Molecular Technology (Guangzhou) Co., Ltd. has been established with a registered capital of 500 million yuan, focusing on medical research and development, investment activities, and sales of Class II medical devices [1][2]. Company Information - The legal representative of the company is Kong Jian, and it is wholly owned by Baiyunshan (600332) [1]. - The company is registered in Huangpu District, Guangzhou, Guangdong Province, with a business scope that includes medical research and experimental development, technology services, and sales of medical devices [2]. Registration Details - The company was registered with a unified social credit code of 91440112MAEWX6L36M and has a business duration until September 30, 2025, with no fixed term thereafter [2]. - The registration address is located at Yichuang Street, Knowledge City, Huangpu District, Guangzhou [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 董事會 中國廣州，2025年10月14日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2025年10月28日（星期 二）舉行董事會會議，藉以審議及批准本公司及其附屬公司截至2025年9月30日止九個月未經審計財 務業績及處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 ...

格隆汇10月14日丨白云山(00874.HK)公布，谨定于2025年10月28日(星期二)举行董事会会议，藉以审议 及批准公司及其附属公司截至2025年9月30日止九个月未经审计财务业绩及处理其他事项(如有)。 ...

格隆汇10月14日丨白云山(00874.HK)公布，谨定于2025年10月28日(星期二)举行董事会会议，藉以审议 及批准公司及其附属公司截至2025年9月30日止九个月未经审计财务业绩及处理其他事项(如有)。 ...